The new opportunities of treatment of non-alcoholic steatohepatitis
Journal Title: Сучасна гастроентерологія - Year 2018, Vol 0, Issue 1
Abstract
Objective — to evaluate the efficacy and safety of the dietary supplement Schisandrin®, 250 mg tablets (manufacturer Pharmacom Ltd.) in patients with non-alcoholic steatohepatitis. Materials and methods. The investigation involved 40 patients (18 (45 %) men and 22 (55 %) women) with non-alcoholic steatohepatitis (NASH), aged 25 to 65 years old (the mean age 43.6 ± 11.3 years). The control group consisted of 10 healthy subjects. Clinical examinations included assessment of data of anthropometric measuring, blood pressure, determination of serum levels of C-reactive protein (CRP) and TNF-alpha in serum, degree of liver steatosis. The treatment was performed with the drug Schisandrin® for 12 weeks in different dosage regimens: I group — 20 patients receiving the drug Schisandrin® 1 tablet 3 times a day; II group — 20 patients who received the drug Schisandrin® for 2 tablets 3 times a day. Results. In the course of treatment, there was a significant dynamics of the main clinical manifestations, i.e. symptoms’ removal or relief, which more rapidly and substantially reduced in patients of group II, as well as decreased activity of the inflammatory process in the liver tissue. The intake of Schisandrin® significantly reduced the increased ALT and AST activity and level of cholestasis markers in patients with NASH, this effect was dose-dependent, too. By the end of third months of therapy, a decrease in the level of high-sensitivity CRP and serum TNF-α levels in the examined patients was achieved, more substantial changes were observed in patients of group II. The improvement of ultrasound characteristics has been revealed, including tendency towards normalization of the acoustic density and liver size due reduction of steatosis degree. Conclusions. It has been demonstrated that Schisandrin® had a positive effects on the NASH course, with a higher efficacy and dose-dependent effects in the treatment regimen of 2 tablets 3 times a day for 3 months. This dose proved to be highly safe and well tolerated. Schisandrin® can serve as an alternative to the treatment of patients with non-alcoholic fatty liver disease at the NASH stage, not only in the stage of activation of the inflammatory process in the liver tissue, but also at the stage of supportive therapy in order to prevent the disease progression.
Authors and Affiliations
G. D. Fadieienko, O. V. Kolesnikova, T. A. Solomenseva
Keywords
Related Articles
- EP ID EP276249
- DOI -
- Views 119
- Downloads 0
Adenomak — new possibilities in a hepatotherapy
-
Complex treatment of non-alcoholic fatty liver disease: experience of the use of hepatoprotectors
Objective — to evaluate the complex therapy effects at the levels of cytokeratin (CK)-18, fibroblast growth factor (FGF)-21 and metabolic parameters of nonalcoholic fatty liver disease (NAFLD) patients. Materials and...
Personal and situational anxiety in young patients with the combined course of gastroesophageal reflux disease and autoimmune thyroiditis
Objective — to assess the psychoemotional status of young patients with gastroesophageal reflux disease (GERD) associated with autoimmune thyroiditis (AIT). Materials and methods. The examinations involved 57 students w...
Modern approaches to the treatment of combed non-alcoholic fatty liver disease and cardiovascular disease
Non-alcoholic fatty liver disease (NAFLD) is a major cause of chronic liver disease and it progresses from simple steatosis to steatohepatitis, fibrosis and cirrhosis. It has been proven that NAFLD is a multisystem disea...
The place of domperidone in the treatment of comorbid pathology of esophagus and stomach (a clinical case)
It has been established that around 20 % of patients with gastroesophageal reflux disease (GERD) have clinical symptoms of the functional gastric dyspepsia, and 20 — 30 % of patients with predominantly non-erosive reflux...